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In mice, H-2 antigens coded for by genes in the major histocompatibility complex 
(MHC) 1 have a directive influence on the specific recognition of syngeneic tumor cells 
by cytolytic T  lymphocytes (CTL) irrespective of the origin of the tumor. Thus, joint 
recognition  of H-2  and  tumor  antigens  by  syngeneic  CTL  has  been  reported  for 
tumors induced by murine leukemia viruses (MuLV;  1-6), by Simian virus-40 (SV40) 
(7,  8),  and  by Herpes simplex  virus  (9),  as  well  as  for chemically  induced  tumors 
whose antigenic structure has not yet been clearly defined (10). The general consensus 
is that the MHC antigens involved in the recognition of the tumor target cell by the 
CTL are restricted to the antigens coded by two genes, H-2K and H-2D; the antigens 
coded by genes in  the H-2I region and  in  other regions of H-2 do not  appear to be 
required  for the recognition event  (5,  11-13).  Finally, the involvement of H-2K and 
Ho2D  has  been  shown  not  to  be equivalent  in  all  cases,  such  that  tumor  antigen 
recognition by CTL was preferential for an association of tumor antigen with H-2K 
or H-2D antigen  (2,  5,  11-13), depending on the origin of the tumor and on the H-2 
haplotype of the  CTL.  Other studies  have shown  that  this  preferential  recognition 
can be controlled by immune response (Ir) genes (11,  14,  15). 
We  recently  reported  (5)  that  recognition  of a  syngeneic  Gross  MuLV-induced 
tumor by CTL from BALB/c (H-2 a) mice appeared to involve the linked recognition 
of tumor antigen with H-2K a antigen exclusively. However, efficient recognition of a 
syngeneic Gross MuLV-induced  tumor by CTL from BALB.B  (H-2~  mice occurred 
in  association  with  either  H-2K  b or H-2D  b antigen  (5,  16),  in  apparent  contradic- 
tion  to  results  reported  by Green  and  colleagues  (17)  who  showed  that  CTL from 
C57BL/6  (H-2  e) mice recognized a  syngeneic Gross MuLV-induced  tumor in prefer- 
ential association with H-2K  b, not H-2D  b antigen. 
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At  least  three  possible explanations  can  be offered  for this  preference,  or  lack of 
preference, exhibited by CTL for a particular association of tumor antigen with H-2K 
or H-2D antigen.  (a)  The intensity  of CTL-mediated  lysis is strictly  regulated  by Ir 
genes,  resulting  in  the  more  efficient  recognition  of  certain  tumor-H-2  antigen 
combinations.  (b) In the case of MuLV-induced  tumors, the viral protein recognized 
by  tumor-specific  CTL  may  have  different  affinities  for  H-2K-  or  H-2D-coded 
molecules,  and  in  consequence  would  be  exposed  on  the  cell  surface  mainly  in 
association  with  one  or  the  other  of these  two  H-2 antigens  (12,  18).  (c)  The  viral 
protein recognized by CTL does not  possess a  preferential  binding  affinity for H-2K 
or H-2D antigen;  rather, there are quantitative  differences in the amounts of H-2K or 
H-2D antigen  exposed on the tumor cell surface due to metabolic or genetic control 
mechanisms at the tumor cell level (19). 
The  present  communication  describes  comparative  quantitative  experiments  de- 
signed  to  study  the  expression  of H-2K d  and  H-21~  antigens  by  three  different 
leukemia cell lines induced by Gross MuLV  in BALB/c (H-2 a) mice. The preferential 
recognition of Gross MuLV-induced  tumor antigen with H-2K d or H-2D a antigen by 
tumor-specific CTL from BALB/c mice was correlated with these quantitations.  The 
three BALB/c tumor cell lines studied  differed in the amounts of H-2K  a and H-2D  a 
antigens that they expressed on the cell surface, and these variations were reflected in 
their  quality  as target  cells  to Gross MuLV-specific  CTL  from  BALB/c  mice.  Our 
results indicate that restriction of tumor-specific CTL activity by H-2 can be directed 
at  the  target  cell  level  by  the  quantitative  modulation  of H-2K  or  H-2D  antigen 
expression, and suggest that separate tumors induced by the same MuLV  in the same 
or in H-2-congenic strains of mice can vary in the absolute amounts of H-2K or H-2D 
antigen expressed on the cell surface. 
Materials  and  Methods 
Mice.  All mice were bred at the Albert Einstein College of Medicine, Bronx, N. Y., or at 
H~Spital Cochin, Paris, from breeding pairs provided by Dr. F. Lilly. The inbred strains used 
included C57BL/6  (B6, H-2  b) and the H-2-congenic strains BALB/c (H-2a), BALB.B  (H-2b), 
and BALB.G (H-2g). 
Tumor Cells.  The  following continuous  leukemia  cell  lines  induced  by Gross  MuLV  in 
b  various congenic strains of mice were used: B.GV cells (H-2  b, H-2KbD, BALB.B), C.GV cells 
(1-1-2  d,  H-2KaD  a,  BALB/c);  H-2-recombinant  cells  G.GV  (H-2  g,  H-2KaD  b,  BALB.G)  and 
5R.GV  (H-21~, H-21(°D a,  BALB.5R);  and  F1  hybrid  B/CFi.GV  cells  (H-2  b/d,  [BALB.B  × 
BALB/c]F1). The origin and characteristics of these cell lines have been described previously 
(5). In addition, two new cell lines designated "C.GV-300" and "C.GV-302" were induced in 
BALB/c mice by infection with Gross MuLV and were established as continuous suspension 
cultures (see Results), according to the method described by Freedman and Lilly (20). All cell 
lines were maintained as stationary suspension cultures in Eagle's minimal essential medium 
supplemented with 10% fetal bovine serum. 
Antisera.  The  following  mouse  antisera  were  prepared  in  our  laboratories  by  repeated 
immunization:  anti-H-2  b  serum  ([BALB/c  ×  Call]F1  anti-EL4  [H-2  b]  leukemia  cells); 
anti-H-2D  b (H-2.2) serum (BALB/c anti-BALB.G spleen cells); anti-H-2K  b (H-2.33) serum ([A 
×  BALB.G]F1 anti-BALB.B spleen cells); anti-H-fi  t serum ([C57BL/6 × C57BL/10.BR]F1 anti- 
Meth-A [H-2 d] leukemia cells);  anti-H-2K  a (H-2.31) serum (BALB.B anti-BALB.G spleen cells; 
absorbed twice on one-half volumes of packed B10.A spleen cells);  anti-H-2D  d (H-2.4) serum 
(BALB.G anti-BALB/c  spleen cells);  anti-Gross leukemia virus-induced  cell surface antigen 
(GCSA)  serum  ([BALB.B  ×  BALB/c]F1  anti-B/CF1.GV  leukemia cells).  Goat  antiserum  to 
Rauscher MuLV gp69/71 antigen was obtained through the Office of Program Resources and F.  PLATA,  A.-F. TILKIN, J.-P.  LI~VY, AND F.  LILLY  1797 
Logistics, Viral Oncology Division, National Cancer Institute, National Institutes of Health, 
Bethesda, Md. All antisera were heat inactivated at 56°C for 30 min. 
Lymphocyte Cultures.  Gross  MuLV-specific CTL  were  generated  in  syngeneic secondary 
mixed leukocyte-tumor cell cultures (MLTC)  from spleen cells of primed mice, as described 
elsewhere (5).  CTL specific for H-2 alloantigens were generated in primary mixed leukocyte 
cultures (16, 21). 
Lymphocyte Clones.  CTL clones were derived from  lymphocytes harvested in  MLTC  and 
distributed in muhiwell plates at limiting dilutions ranging from 0.5  to  1.0 cell/well in the 
presence of 30% conditioned medium and  1 ×  10  e x-irradiated (3,000  rad) syngeneic spleen 
cells. Cloning efficiency ranged from 64 to 77%. Conditioned medium came from rat spleen 
cells incubated at 37°C for 36 h with 5 ~tg/ml concanavalin A. Each CTL culture was fed every 
4-5  d  with conditioned medium;  after 4  wk each clone was transferred into upright  tissue 
culture flasks and expanded by the addition of 30% conditioned medium, 3 X  106 x-irradiated 
(3,000  rad) syngeneic spleen cells, and  1 ×  10  e x-irradiated (5,000  rad) tumor cells as a source 
of antigen. 
51Cr Release Cytotoxicity  Assays.  Cell-mediated antitumor cytolytic activity was detected using 
a  modification (5) of the method of Brunner et al. (22).  All assays were terminated after 6 h 
incubation  at  37°C.  Spontaneous  release  values  varied  between  4  and  15%  of the  total 
incorporated  label.  Antibody- and  complement-mediated  cytolysis was  detected  with  the 
method originally described by Sanderson  (23)  using 2.5  X  104 SlCr-labeled target cells and 
agarose-adsorbed rabbit complement (24) in 45-rain assays. 
Inhibition Assays.  CTL specificity for target antigens was analyzed by two approaches: (a) 
addition of varying numbers of competitor target cells to the SXCr release cytotoxicity assay (5) 
and (b) addition of anti-H-2 sera at varying dilutions, in the absence of complement, to the 51Cr 
release cytotoxicity assay (1, 11). The percentage of inhibition of CTL-mediated cytotoxicity by 
both approaches was calculated according to the formula: control -  experiment/control ×  100, 
where  control  was  the  specific  cytotoxic  activity  detected  in  positive  control  wells;  and 
experiment was the experimental cytotoxicity values obtained from wells containing competitor 
target cells or blocking antisera. 
Quantitative Absorption ofSpedfic Antisera.  All sera to be absorbed were used at dilutions giving 
40-50% lysis of  a standard target cell following incubation in the presence of rabbit complement. 
Cell surface antigens were quantitated by incubating 100 pl of specific antisera with varying 
numbers of normal spleen cells or tumor cells for 30 min at 0°C. The cells were then removed 
by centrifugation and the remaining cytotoxic activity of the antiserum was assayed on 51Cr- 
labeled target cells in the presence of rabbit complement (see above), and was compared to the 
activity of sham-absorbed antiserum at the same dilutions. The percentage of absorption of 
specific antiserum activity was calculated with the formula given above. 
Results 
Establishment and Initial Characterization of New BALB/c Gross MuL V-induced Tumor Cell 
Lines.  Six BALB/c mice from the same litter were inoculated with 0.05 ml of a  cell- 
free extract of Gross MuLV  (25) on the first day following birth. Four mice developed 
leukemia 3-5  mo later, and upon inspection had hyperplastic thymus, spleen, liver, 
and/or  mesenteric  lymph  nodes.  The  leukemic  lymphoid  organs  were  removed, 
minced  separately and  inoculated  subcutaneously  into  adult  BALB/c  mice  of the 
same sex as the leukemic mouse, according to the protocol established by Freedman 
and  Lilly  (20).  Following the  appearance  of solid tumors,  the  leukemic cells were 
extracted and established as suspension cultures. After 10 passages in vitro each tumor 
cell line was checked for its ability to incorporate 51Cr and for its quality as a  target 
to Gross MuLV-speeific CTL.  Two  particular cell lines, C.GV-300  and  C.GV-302, 
were selected for extensive study. These two lines originated from the same leukemic 
thymus  but  were  passaged as subcutaneous  tumors  in  two  different adult BALB/c 
mice  (numbers  300  and  302),  and  subsequently  were  maintained  as  independent 1798  VARIABLE  EXPRESSION  OF  H-2  ANTIGENS 
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FIG.  1.  Detection  of H-2K  a and H-2D  a antigens on the surface of (A) C.GV cells, (B) C.GV-300 
cells, and (C) C.GV-302 cells by the incubation of SZCr-labeled tumor cells in the presence of anti- 
H-2 serum and rabbit complement. O, anti-H-2  a serum; ©, anti-H-2.4 (H-2D  a) serum; I, anti- 
H-2.31 (H-2K  a) serum; and rl, normal mouse serum. 
suspension  cultures,  Preliminary experiments  revealed  that  these  two  "sister"  lines 
differed with  respect  to their  qualities  as targets to syngeneic Gross MuLV-specific 
CTL, C.GV-300 cells being more susceptible to lysis than C.GV-302. 
Cell-Surface  Antigen Expression by Gross MuL V-mduced Tumor Cell Lines.  In view of the 
differences in their qualities as target cells to Gross MuLV-specific CTL, lines C.GV- 
300 and C.GV-302 were analyzed serologically with respect to their principal surface 
antigens in comparison with the C.GV line established previously (5,  16). Detection 
of the GCSA (26) and of the MuLV glycoprotein gp70 by quantitative absorption of 
specific antisera showed that the three cell  lines were positive in comparable degrees 
for both antigens (data not shown). 
In contrast, analysis of the expression of H-2  antigens revealed  major differences 
among the three cell lines.  Fig.  1 indicates that  all three lines expressed a  sufficient 
number of surface molecules of H-2.4 (H-2D a) and H-2.31  (H-2K  a) antigens for tysis 
to occur following incubation in the presence of monospecific anti-H-2 sera and rabbit 
complement. However, as shown in Fig.  2, quantitative absorption of these antisera 
with  varying numbers of normal BALB/c spleen cells  or with C.GV, C.GV-300, or 
C.GV-302 cells  indicated that C.GV cells  expressed barely detectable levels  of H-2.4 
(H-2D a)  antigen, whereas C.GV-300 cells  expressed relatively large amounts of the 
same antigen  (Fig.  2 A). C.GV-302 cells  were intermediate,  since they expressed  7.5 
times less H-2.4 antigen than C.GV-300 cells and at least  10 times more H-2.4 antigen 
than C.GV cells. Quantitation of the amount of H-2.31 (H-2K  a) antigen expressed on 
the three cell lines (Fig.  2 B) showed that the C.GV and C.GV-300 lines were roughly 
equivalent and that the C.GV-302 cell  line expressed three times less H-2.31 antigen 
than  the  C.GV  or the C.GV-302 line.  The apparent  scarcity of H-2.31  antigen  on 
these tumor cells relative to normal BALB/c spleen cells could be due to the presence 
of contaminating anti-Ia antibodies in the anti-H-2.31 serum in spite of absorption of 1799 
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FIc. 2.  Quantitation of H-2D  a and H-2K  a antigen expression following absorption of (A) anti- 
H-2.4 (H-2D  a) serum and (B) anti-H-2.31 (H-2K  a) serum by BALB/c spleen cells (O), C.GV cells 
(C)), C.GV-300 cells (11), C.GV-302 cells (~,  or  BALB.B spleen cells (A). Cytotoxicity was 
determined by incubation of 51Cr-labeled BALB/c spleen cells in the presence of the absorbed sera 
and rabbit complement. Unabsorbed sera gave the following degrees ofcytotoxicity in the presence 
of rabbit complement: anti-H-2.4 serum (1/50), 54%; anti-H-2.31 serum (1/100), 40%; normal 
mouse serum (1/50), 4%. 
the antiserum on B10.A spleen cells (see Materials and Methods).  Since spleen cells 
are rich  in  Ia antigens,  as opposed  to  the  tumor cells  in  question,  an  exaggerated 
difference in  the  binding of anti-H-2.31  serum antibodies  would  be observed.  This 
problem  will  be  resolved  by  quantitation  of  H-2.31  antigen  using  monoclonal 
anti-H-2.31  antibodies.  The present  results thus indicated  that  the three tumor cell 
lines  studied  varied  widely  in  the  amounts  of H-2  antigens  that  they  expressed, 
C.GV-300 cells expressing relatively high levels of both H-2.4 and H-2.31  antigens, 
C.GV-302 cells being intermediate,  and C.GV cells expressing high levels of H-2.31 
antigen but barely detectable levels of H-2.4 antigen. 
A  further confirmation  of the  disparity  in  H-2K  a and H-2D  d antigen  expression 
among our tumor cell lines came from the analysis with H-2-specific CTL.  Table I 
shows  that  all  three  tumor  cell  lines  were  susceptible  to  lysis  by  BALB.B  anti- 
BALB/c  (anti-H-2  a) CTL. Analysis with monospecific CTL showed that C.GV-300 
cells were killed by both anti-H-2K  a and anti-H-2D a CTL. C.GV-302 cells were also 
killed by both types of CTL, but 3-10 times less efficiently. Finally, C.GV cells were 
only killed by anti-H-2K  a CTL. The degree of specificity of these CTL was indicated 
by the fact that none killed B.GV (H-2  b) cells efficiently, that anti-H-2K  a CTL killed 
H-2-recombinant G.GV  (H-2KaD b)  cells and not  5R.GV  (H-2KbD  a)  cells, and that 
anti-H-2D d CTL killed 5R.GV cells and not G.GV cells. The data shown in Table I 
thus  indicated  that  the  expression  of relatively large  amounts  of H-2  antigen  was 
required on the surface of the target cells in order for efficient CTL-mediated lysis to 
occur.  Moreover,  efficient  complement-mediated  lysis  in  the  presence  of specific 
antibody  required  the  expression  of much  smaller  amounts  of H-2  antigen,  the 
expression of a  few H-2 molecules on  the cell surface probably being sufficient  for 
antibody  binding  to  occur  and  for  lethal  membrane  damage  to  be  initiated  (cf. 
Fig.  1). 
Effect of H-2 Antigen Expression  on CTL Generation and Activity.  Previously, we reported 
that the BALB/c C.GV cell line had the capacity of inducing large amounts of Gross 1800  VARIABLE EXPRESSION OF H-2  ANTIGENS 
TABLE  [ 
Detection of H-2K  a and H-2D  a Antzgens on C.GV Tumor Cells Using H-2-spec~c  CTL 
Target  cells  Percentage  of specific 5~Cr release 
H-2  BALB.B  BALB.B  BALB.G 
Geno-  Anti-BALB/c  Anti-BALB.G  Anti-BALB/c 
Designation  type  (anti-H-2KaD  a)  (anti-H-2K  a)  (anti-H.2D  a) 
K  D  100  30  10  3  100  30  10  3  100  30  10  3 
C.GV  d  d  19  17  12  0  21  t7  2  0  0  0  0  0 
C.GV-300  d  d  62  59  43  13  56  54  20  9  46  38  15  2 
C.GV-302  d  d  25  21  5  1  27  24  5  0  18  6  3  0 
G.GV  d  b  34  32  12  5  48  44  31  14  0  0  0  0 
5R,GV  b  d  40  30  22  3  14  8  0  0  37  21  10  1 
B.GV  b  b  7  2  3  0  7  4  3  1  11  4  1  0 
CTL were harvested after 6d incubation in MLC, and tested for cytotoxicity on a panel of 5~Cr-labeled 
target cells at the indicated lymphocyte to target cell ratios in a 6-h assay. 
TABLE II 
H-2 Specificity of GV-spec~c CTL from BALB/c and BALB.B Mice 
Target cells  Percentage of specific 51Cr release 
H-2 Genotype  BALB/c Anti-C.GV  BALB/c Anti-C.GV-300  BALB/c Anti-C.GV-302  BALBB Anti-B GV 
Designation 
K  D  30:1  10:1  3:1  l:l  30:1  I(1:1  3:1  1:1  30:1  10:1  3:1  I:1  30:1  10:1  3:1  1:1 
C.GV  d  d  6  4  0  0  t i  2  0  0  2  i  0  0  0  0  0  0 
C.GV-300  d  d  43  25  12  6  66  47  3(I  13  33  t5  15  2  7  3  (1  0 
C.GV-302  d  d  35  22  17  4  54  22  9  7  29  1  ?  9  4  6  4  2  (1 
B/C F~.GV  b/d  b/d  16  8  3  1  28  11  5  2  1B  12  9  1  12  4  I  0 
GGV  d  b  43  26  16  6  55  32  14  I 1  19  12  10  5  26  14  10  2 
5R.GV  b  d  (1  1  (1  (1  36  18  7  2  9  5  2  (1  16  9  4  0 
B.GV  b  b  (1  0  0  0  2  1  1  ~)  2  0  3  2  66  42  27  10 
Lymphocytes were harvested after 6 d  incubation in secondary MLTC,  and tested against a  panel of ~lCr-labeled 
target cells at  the indicated lymphocyte to target cell ratios in a  6-h assay. 
MuLV-specific CTL in secondary MLTC, but that C.GV cells themselves were very 
poor  targets  to  the  CTL they  induced  (5).  Furthermore, the  Gross  MuLV-specific 
CTL generated were  restricted to Gross MuLV-induced cells that  expressed H-2K  ~ 
antigen;  H-2D d  antigen  appeared  to  be  irrelevant  for  CTL  recognition  of  the 
target cell to occur (5). We have consistently reproduced this paradoxical situation: 
Table II shows that BALB/c (H-2  a)  CTL induced by C.GV cells were incapable of 
killing  C.GV  target  cells,  but  killed  C.GV-300  and  C.GV-302  cells  efficiently. 
B/CF1.GV (H-2  b/d)  cells, induced by Gross MuLV in (BALB.B ×  BALB/c)Fx hybrid 
mice, were also susceptible to lysis by C.GV-induced CTL, as were G.GV (H-2KaD b) 
tumor cells. As reported previously (5), 5R.GV (H-2KbD  a) and B.GV (H-2  b) cells were 
insensitive to lysis mediated by C.GV-induced CTL. 
Attempts to generate CTL in BALB/c mice against syngeneic C.GV-300 or C.GV- 
302  tumor  cells  showed  that  these  two  cell  lines,  in  contrast  to  C.GV  cells,  were 
capable  both  of inducing Gross  MuLV-specific CTL  in  MLTC  and  of serving as 
targets  to  the lytic activity of these CTL. Table II shows that  C.GV-300 cells were 
both better stimulators of CTL differentiation in MLTC  and better targets to CTL 0 
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FIG.  3.  Inhibition of CTL-specific activities by incubation ofSlCr-labeled C.GV-300 (H-2  a) target 
cells with anti-H-2 sera in the absence of  complement. CTL were assayed at a ratio of 10 lymphocytes 
to l target cell. Cytotoxicity values in the presence of normal mouse serum (1/2-1/486)  were: (A) 
BALB/c anti-C.GV CTL, 31%; (B) BALB/e anti-C.GV-300 CTL, 25%; (C) B6 anti-BALB/c CTL, 
17%. 0, anti-H-2 a serum; O, anti-H-2.4 (H-2D  a) serum;., anti-H-2.31 (H-2K  d) serum. 
lytic activity  than  either  C.GV-302  or C.GV cells.  Table  II also  demonstrates  that 
C.GV-300  cells  were  capable  of inducing  Gross  MuLV-specific  CTL  capable  of 
recognizing tumor antigen in association with either H-2K  a antigen (i.e., G.GV target 
cells)  or  H-2D  a  antigen  (i.e.,  5R.GV  target  cells).  C.GV-302  cells  induced  CTL 
restricted mainly to H-2K a, although detectable lytic activity was also directed against 
H-2D  a antigen.  That  these CTL were specific for the H-2 a haplotype was indicated 
by  the  fact  that  they  killed  C.GV-300  and  C.GV-302  (H-2 a)  cells,  as  well  as 
B/CFx.GV  (H-2  b/a) cells, but not B.GV (H-2 b) cells. The latter, however, were killed 
by B.GV-immune CTL from BALB.B mice (Table II), which could recognize tumor 
antigen in association with either H-2K  b antigen  (i.e.,  5R.GV cells) or H-2D b antigen 
(i.e.,  G.GV cells). The results summarized in Table II thus showed that Gross MuLV- 
specific CTL recognizing H-2K and H-2D antigens could be generated in MLTC with 
immune spleen cells from either  BALB/c or BALB.B mice;  and  that,  in the case of 
BALB/c mice,  the  presence  of H-2Da-specific  CTL  depended  on  the  choice of the 
Gross MuLV-induced tumor cells used as stimulators  in MLTC. 
That C.GV-300 tumor cells are capable of inducing Gross MuLV-specific CTL in 
BALB/c  mice  specific  for either  H-2K  a  or H-2D  a  antigen  was  confirmed  by three 
independent  approaches: 
(a)  Inhibition  of CTL-spec~'c  activity  by anti-H-2 sera in  the  absence of complement:  Fig.  3 
summarizes  data  concerning  the  inhibition  by  antibodies  of Gross  MuLV-specific 
CTL generated in MLTC  from BALB/c immune spleen cells. C.GV-300 tumor cells 
were chosen as  target  cells  throughout  since they express  optimal  amounts  of both 
H-2K  a and H-2D a antigens.  Stimulation  in MLTC  with C.GV tumor cells  (Fig. 3 A) 
resulted  in CTL that could be blocked by incubation of the 51Cr-labeled  target cells 
with anti-H-2  a serum (containing antibodies against both H-2K  a and H-2D  a antigens) 
and with anti-H-2.31  (H-2K  a) serum. Anti-H-2.4 (anti-H-2D a) serum failed to block I
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TABLE III 
H-2 Specificity of Cloned GV-immune CTL from BALB/c Mice 
1803 
Clone group 
Cytotoxic activity detected on  Frequency* 
C.GV-300  G.GV  5R.GV  (H_2KaDa)  (H.2KaDb)  (H_2K~D  a)  Anti-C.GV  Anti-C.GV-300 
I  +  +  -  0.43 (18/42)  0.45 (9/20) 
II  +  -  +  0.12 (5/42)  0.35 (7/20) 
III  +  +  +  0.33 (14/42)  0.20 (4/20) 
CTL clones were grown  by limiting  dilution  from  BALB/c  anti-C.GV  or  BALB/c  anti-C.GV-300 
lymphocytes. CTL  were generated  in  secondary  MLTC  and  distributed  in  multiwell  plates at  a 
concentration of  0.5 cell/well. Starting on day 4 after distribution, the wells were inspected microscopically 
every day, and those cultures which presented single proliferating cell clusters were defined as lymphocyte 
clones. Following expansion, each clone was tested for cytotoxicity three different times on a panel of 
51Cr-labeled target cells in 6-h assays. 
* Number of clones positive/total number of clones assayed. 
CTL activity, indicating the absence of Gross MuLV-specific CTL which recognized 
tumor antigen in association with H-2D  ~ antigen. 
Fig. 3 B indicates that C.GV-300 tumor cells generated two independent subsets of 
Gross  MuLV-specific  CTL,  one  subset  recognizing  H-2K  a  and  the  other  H-2D  ~ 
antigen,  because  both  anti-H-2.31  and  anti-H-2.4  sera  blocked CTL-mediated  lysis 
efficiently.  It  should  be  noted  that  neither  of the  two  monospecific antisera  could 
inhibit  killing completely at  any of the dilutions  assayed,  thus  suggesting the  inde- 
pendent  activity  of two  subsets  of CTL.  An  analogous  finding  was  observed  with 
alloantigen-specific CTL  (Fig.  3 C)  generated by stimulating C57BL/6  ("B6,"//-2  b) 
spleen cells with x-irradiated  normal BALB/c (H-2  u)  spleen cells in MLC: one CTL 
subset  (i.e., anti-H-2K  u CTL) was inhibited by anti-H-2.31  serum, whereas a different 
subset  appeared  to be inhibited  by anti-H-2.4 serum, neither serum  giving complete 
inhibition of CTL activity. 
(b ) Competitive inhibition of CTL specific activity by unlabeled tumor cells: Fig. 4 A shows that 
BALB/c anti-C.GV CTL, when tested on SaCr-labeled C.GV-300 target cells, can be 
inhibited  efficiently by the addition  of unlabeled  C.GV,  C.GV-300,  C.GV-302, and 
G.GV (H-2KaD  b) cells; 5R.GV (H-2KbD  't) and B.GV (//-2  b) cells were poor inhibitors 
of cytotoxicity,  thus  indicating  that  BALB/c  anti-C.GV  CTL  were  restricted  to 
H-2K  d antigen. On the other hand, Fig. 4 B shows that BALB/e anti-C.GV-300 CTL 
were inhibited  by both G.GV and 5R,GV cells, as well as by C.GV, C.GV-300, and 
C.GV-302 cells.  C.GV-300 cells,  which express  appreciable  amounts  of both H-2K  u 
and  H-2D  ~ antigens,  were  better  inhibitors  of CTL  activity  than  either  G.GV  or 
5R.GV cells, indicating the existence of H-2K  u- and H-2Dd-restricted  CTL subsets. 
(c)  Specificity analysis of cloned CTL:  Table  III summarizes  the  results  obtained  after 
cloning  BALB/c  anti-C.GV  CTL  and  BALB/c  anti-C.GV-300  CTL.  CTL  clones 
were obtained by limiting dilution of CTL from MLTC and expansion in the presence 
of conditioned  medium,  x-irradiated  BALB/c  spleen  feeder  cells,  and  x-irradiated 
C.GV or C.GV-300 tumor cells as a source of antigen. When assayed for cytotoxicity 
on a panel of 51Cr-labeled tumor cells, the CTL could be grouped into three categories. 
Group  I  contained  the  largest  number of clones  (43-45%)  and  included  the  cloned 
CTL  that  lysed both  C.GV-300  and  G.GV  (H-21~D b)  target  cells,  but  not  5R.GV 
(H-2K~D  a)  ceils; this pattern  of specificity indicated  that  the CTL clones in group I 1804  VARIABLE EXPRESSION  OF H-2 ANTIGENS 
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Fie.  5.  Inhibition of  CTL-specific activities by incubation of~lCr-labeled B.GV (H-2  ~) target cells 
with anti-H-2 sera in the absence of complement. BALB.B anti-B.GV CTL (A) and BALB/c anti- 
B6 CTL (B) were tested in a 6-h assay at  a ratio of 10 lymphocytes to  1 target cell, and gave 
cytotoxicity values of 33 and 41%, respectively, in the presence of normal mouse serum (1/3-1/243). 
O, anti-H-2  b serum; O, anti-H-2.2 (H-2D  b) serum; II, anti-H=2.33 (H-2K  b) serum; I'q, anti-H-2.2 + 
anti-H-2.33 sera (1:1). 
were restricted to H-21~ antigen. Group II included CTL clones that recognized and 
killed  C.GV-300  and  5R.GV  cells,  but  not  G.GV  cells,  and  consequently  were 
restricted to H-2D a antigen. Only 12% (5/42)  of the cloned BALB/c anti-C.GV CTL 
fell in this category; however, a  significantly higher proportion  (i.e.,  35% or 7/20)  of 
CTL clones fell in this category when BALB/c anti-C.GV-300 CTL were considered. 
Group III included CTL clones that killed C.GV-300, G.GV, and 5R.GV target cells; 
this group included 20-33% of all clones. Extended analysis showed that CTL clones 
in group III also killed an assortment of "irrelevant"  target cells, indicating the lack 
of an astringent  degree of specificity for the  immunizing  tumor cell. 2 These  results 
consequently  showed  that  BALB/c  anti-C.GV  CTL  and  BALB/c  anti-C.GV-300 
CTL consisted of at  least  three subsets  of cytolytic T  cells,  two subsets  recognizing 
either H-21~  or H-2D  a antigen  independently,  and  a  third  subset  recognizing both 
antigens.  Furthermore,  the choice of the tumor cell used to generate CTL appeared 
to determine  the  relative  proportion  of each CTL subset.  A  detailed  description  of 
these CTL clones is provided in a separate communication. 2 
Analysis ofBALB.B anti-B.GVCTL Specificities.  In a previous report (5) we indicated 
that  CTL  from  BALB.B  (H-2  b)  mice  immunized  against  syngeneic  Gross  MuLV- 
induced B.GV cells recognized tumor antigen on B.GV cells in association with either 
H-2K b or H-2D b antigen.  This  conclusion  was  drawn  from studies  concerning  the 
direct lysis ofG.GV (H-2KdD b) and 5R.GV (H-2KbD a) target cells by BALB.B CTL. 
A  new series  of experiments  confirmed the  latter  observations.  Fig.  5A shows that 
CTL-specific activity directed against 51Cr-labeled B.GV target cells was inhibited by 
anti-H-2  b serum, as well as by anti-H-2.2  (anti-H-2D b) and anti-H-2.33  (anti-H-2K b) 
2 Plata, F. Specificity  studies of cytolitic T lymphocytes (CTL) directed against murioe leukemia virus- 
induced tumors. Analysis by monoclonal CTL. Manuscript submitted for publication. F.  PLATA,  A.-F.  TILKIN, J.-P.  LI~VY,  AND  F.  LILLY 
TABLE  IV 
H-2 Specificity of CTL Clones Generated  from BALB. B Anti-B. G V Lymphocytes 
1805 
Cytotoxic activity detected on 
Clone group  B.GV  G.GV  5R.GV  Frequency* 
(H-21~D  b)  (H-2KaD  b)  (H-21~D  a) 
I  +  +  -  0.48 (12/25) 
II  +  -  +  0.16 (4/25) 
lIl  +  +  +  0.36 (9/25) 
CTL  clones  were  grown  by  limiting  dilution  at  1.0  cell/microplate  well  from 
BALB.B  anti-B.GV  lymphocytes harvested  from  secondary  MLTC.  CTL  clones 
were defined as described for Table III. Each CTL clone was tested for cytotoxicity 
four independent times on a  panel of 5*Cr-labeled target cells in 6-h assays. 
* Number of clones positive/total number of clones assayed. 
sera.  Moreover,  a  I:1  mixture of anti-H-2.2  and  anti-H-2.33  sera  inhibited  CTL 
activity more efficiently than either serum  alone. These results thus  indicated  that 
Gross MuLV-induced tumor antigens could be recognized in association with either 
H-2I~ or H-2D  b antigens, and that each "association" was probably recognized by a 
different  subset  of Gross  MuLV-specific  CTL.  A  control  assay  with  alloantigen- 
specifiC BALB/c anti-B6 (anti-H-2  b) CTL assayed on B.GV target cells (Fig. 5 B) also 
indicated the existence of two independent subsets of CTL, one recognizing H-2K  b 
antigen and the other H-2D  b. 
The specificity analysis of 25 BALB.B anti-B.GV CTL clones confirmed the results 
above. Table IV shows  that  the majority of these CTL clones  (i.e., 48% or  12/25, 
group I) recognized and killed B.GV cells and G.GV (H-2KaD  a) cells, but not 5R.GV 
(H-2KbD  a)  cells.  The clones  in  group  I  thus  appeared  to recognize Gross  MuLV- 
induced  antigen  in  association  with  H-2K  ¢'  antigen,  and  not  with  H-2D  b  antigen. 
Group II  (four clones)  gave the inverse specificity pattern.  Finally, group III  (nine 
clones) seemed to recognize tumor antigen in association with both H-2D  b and H-2K  b 
antigens, and lacked a  high degree of specificity, as indicated by extended analysis.  2 
These results were analogous to the specificity patterns observed with BALB/c anti- 
C.GV-300 CTL clones, where at least three different categories of CTL clones were 
also identified. 
Discussion 
In  this  study we  have considered by  quantitative  approaches  the  expression of 
H-2K and H-2D antigens on the surface of three different BALB/c tumor cell lines 
induced by Gross MuLV.  Quantitative  absorption of anti-H-2.31  serum  with  cells 
from these  three lines  indicated  that  C.GV and  C.GV-300  cells expressed roughly 
equivalent amounts of H-2K  a antigen, whereas C.GV-302 cells expressed three times 
less H-2I~ antigen than cells from either one of the other two lines (Fig. 2). Moreover, 
expression ofH-2D  d antigen varied widely from one tumor cell line to the other, thus, 
C.GV cells expressed barely detectable amounts, G.GV-300 cells expressed relatively 
large amounts of H-2D  a antigen, and C.GV-302 cells expressed intermediate levels of 
H-2D  d  antigen  (7.5  times less  than  the equivalent  number of C.GV-300 cells).  An 
interesting observation was  that  in  all cases normal  BALB/c spleen cells expressed 
more  (i.e.,  7.5-100  times)  H-2  antigens  than  any of the  BALB/c tumor  cell  lines 1806  VARIABLE EXPRESSION OF H-2 ANTIGENS 
studied.  Furthermore,  it  should  be stressed  that  the C.GV-300  and  C.GV-302  cell 
lines  were  derived  from  the  same  original  Gross  MuLV-induced  thymoma,  and 
divergence with respect to H-2D  a antigen expression must have occurred during the 
course of establishment of the two tumor cell lines as continuous suspension cultures. 
In  this context, Scollay et al.  (27)  have shown  that  thymocyte subpopulations can 
vary significantly in the quantitative expression of 1-1-2 antigens. Likewise, we recently 
reported that MuLV-induced tumor cells can show wide phenotypic variations when 
considered at the clonal level (21).  In view of these facts, it is not surprising that two 
variant cell lines originating from the same neoplasm were selected during the course 
of their establishment as continuous tumor cell lines in vitro. An interesting corollary 
was  that  expression of Gross MuLV-induced cell surface antigens  (i.e., GCSA and 
gp70), as detected by specific antisera, were not significantly altered by the depressed 
expression of H-2D  a antigen in any one of the cell lines studied. 
Analysis of the three cell lines with anti-H-2 CTL yielded results comparable to 
those obtained by serological analysis: all three lines displayed detectable amounts of 
H-2K  a antigen, but varied quantitatively in the expression of H-2D  a antigen (Table 
I). Thus, H-2Dd-specific CTL were not capable of killing C.GV target cells, but killed 
C.GV-300 and C.GV-302 cells.  It was apparent  that, of all the target cells assayed, 
C.GV-300 cells were the most sensitive to lysis mediated by anti-H-2 CTL, possibly 
due to the expression of optimal amounts of H-2K  a and H-2D  a antigens by C.GV-300 
cells. 
The differences in the expression ofH-2D a antigen by C.GV, C.GV-300, and C.GV- 
302 tumor cells affected the H-2 restriction patterns of the Gross MuLV-specific CTL 
which  these tumor cells elicited in  MLTC, as shown  concordantly by experiments 
involving  three  different  technical  approaches:  (a)  inhibition  of CTL  activity  by 
monospecific anti-H-2 sera;  (b) competitive inhibition of CTL-mediated cytotoxicity 
by the addition of excess tumor cells into the reaction mixture; and (c) clonal analysis 
of CTL speeifieities. All three approaches showed that C.GV-300 tumor cells induced 
both  H-2K  a-  and  H-2Da-specific  CTL in  MLTC,  while C.GV  tumor  cells  mainly 
induced H-2Ka-specific CTL. An intermediate situation was observed with C.GV-302 
cells, since they induced both H-2K  a- and H-2Dd-specific CTL; H-2Ka-specific CTL 
were clearly in excess (Table II). 
A similar analysis of  Gross MuLV-specific CTL from BALB.B (H-2  b) mice indicated 
that  syngeneic B.GV  tumor  cells  induced  the  generation  of CTL  that  recognized 
tumor antigen in association with H-2K  b and H-2D b antigens, with a  possible excess 
of H-2Kb-specific  CTL,  confirming our  previous observations  (5,  16).  In  apparent 
contradiction, Green and collaborators (17) indicated that Gross MuLV-specific CTL 
from  C57BL/6  (H-2  b)  mice  recognized  Gross  MuLV-induced  antigens  on  Ec~G2 
(H-2  b) leukemia cells in association with H-2K  b antigen, and not with H-2D b antigen. 
Extrapolation of our results concerning the three tumor cell lines induced by Gross 
MuLV in BALB/c (H-2  a) mice to the H-2  b system leads to the suggestion that B.GV 
cells might express higher quantities of H-2D  b antigen than E~G2 cells, and that the 
proportions of H-2K  b-  and  H-2Db°specific  CTL generated by each tumor cell vary 
accordingly. A direct comparison of these two systems of immunity directed against 
Gross MuLV antigens in H°2  b mice remains to be performed. 
Another unresolved problem is the intriguing dissociation exhibited by tumor cells 
with  respect  to their qualities  as  stimulator cells  for CTL generation  in  syngeneic F. PLATA, A.-F. TILKIN, J.-P. LI~VY, AND F. LILLY  1807 
MLTC, as opposed to their qualities as target cells to tumor-specific CTL in the 51Cr 
release  assay  (5,  12). Both  C.GV-300  and  C.GV-302  leukemia  cells  were  good 
stimulators of CTL generation and were adequate target cells to CTL-mediated lysis, 
although  C.GV-300  cells  proved  to  be  consistently  better  than  C.GV-302  cells 
with respect to both functions. In contrast, as reported previously (5), C.GV cells were 
excellent stimulators of CTL differentiation in syngeneic MLTC but were very poor 
targets  to  Gross  MuLV-specific  CTL-mediated  lysis.  The  minimal  expression  of 
H-2D  d antigen by C.GV cells cannot explain this dissociation completely, since C.GV 
cells  were  adequate  targets  to  alloantigen-specific  CTL  directed  against  H-2K  a 
alloantigen (Table I). Furthermore, C.GV cells express Gross MuLV-induced antigens, 
as determined by serological techniques, and can compete for the lysis of SaCr-labeled 
C.GV-300 target cells (Fig. 4). 
Our experiments suggest that the pattern of H-2 restriction observed among tumor- 
specific CTL might occasionally be directed by the quantitative modulation of H-2K 
or H-2D antigen expression by the tumor cell. The selective shut-down of cell surface 
antigen expression  by eucaryotic cells is  a  phenomenon  that  has been  extensively 
studied in models ranging from protozoa  (28,  29)  to mammalian lymphocytes and 
tumor cells (30-33). The existence of a primitive (from the evolutionary point of view) 
reaction  leading  to  the  suppression  of individual  cell  surface  antigens  has  been 
established. The mechanism underlying the selective repression of H-2 antigens is not 
yet understood; hypotheses have been proposed, ranging from the selection of cells 
having suffered strqctural mutation in H-2 to the selection of cells in which portions 
of chromosome 17 (which contains the MHC) have been selectively inactivated (32, 
33). In this context, Jones and Bodmer (34) have reported the identification of human 
tumor cells  deficient in the expression of cell surface HLA transplantation antigens 
identifiable by specific antibody, suggesting that the repression of a  single gene in 
tumor cells might facilitate escape from the selective pressure of immune surveillance. 
Normal lymphocytes can also show variations in the expression of H-2 antigens; 
Emerson et al. (19) reported data indicating that H-2K, H-2D, and H-2I antigens are 
spontaneously shed at different rates from viable normal lymphocytes in culture, in 
the absence of antibody. Furthermore, the rate of shedding of individual antigens 
varied among lymphocytes from different strains of mice, and this rate was controlled 
by genes mapped to the MHC (19). Because replacement of shed H-2 antigens on the 
cell surface is a  relatively slow process, rapid shedding of an individual H-2 antigen 
and variations in the rate of replacement could lead to quantitative differences in the 
expression of the antigen at the cellular level. 
If this analysis is applicable to tumor cells, H-2 restriction patterns of tumor cell 
recognition  by  tumor-specific CTL  would  be  affected. A  report  by  Gooding  (12) 
recently indicated  that  SV40-transformed  (H-2 k  ×  H-2b)Fa  hybrid cells expressed 
suboptimal amounts of the H-2Kb/SV40  target antigen recognized by specific CTL. 
The same cells,  however, expressed  adequate amounts of SV40  antigen associated 
with H-21~, H-2D  b, and H-2D  k antigens. Although Gooding explained these results 
by invoking an increased avidity of SV40 antigen for H-2K  k relative to H-2K  b antigen, 
a  decrease in the amount of H-2K  b antigen on the cell surface would also provide a 
plausible explanation. 
The mechanism responsible for the variability in H-2 antigen expression by our 
tumor  cell  lines  induced  by  Gross  MuLV  in  BALB/c mice  is  not  understood.  It 1808  VARIABLE EXPRESSION OF H-2 ANTIGENS 
remains to be specified whether this variability is the result of differential rates in the 
shedding of H-2K and H-2D antigens, or whether, on the contrary, it is the result of 
an  activation  phenomenon  of 1-1-2 genes,  such  as  was  reported  by  Meruelo  (35) 
concerning the heightened expression of H-2 antigens on tumor cells after incubation 
in the presence of interferon. 
Summary 
Comparative  quantitative  experiments were  designed  to  study  the  expression  of 
H-2K  a  and  H-2D  a  antigens  on  three  different  leukemia cell lines  induced  by Gross 
murine leukemia virus (MuLV) in BALB/c (//-2  a) mice. The H-2 restriction patterns 
of syngeneic cytolytic T  lymphocytes (CTL)  directed  against Gross MuLV-induced 
tumors were correlated with these quantitations  of H-2K  a and H-2D  d antigens. Our 
results obtained  by quantitative  absorption  of monospecific antisera  indicated  that 
the three BALB/c tumor cell lines expressed different amounts of H-2K  a and H-2D  a 
antigens, with H-2D  a antigen showing the greatest variability in expression because 
it ranged from barely detectable levels to one-eighth  the amount of H-2D  a  antigen 
expressed  on  normal  BALB/c  spleen  cells.  The  H-2  restriction  patterns  of Gross 
MuLV-specific CTL were directly affected by these quantitative modulations in the 
expression  of H-2K  a  and  H-2D  a  antigens,  as  revealed  by  three  independent  ap- 
proaches:  (a) inhibition of CTL activity by monospecific anti-H-2 sera in the absence 
of complement;  (b)  competitive  inhibition  of CTL-mediated  cytotoxicity  by  the 
addition  of excess  tumor cells  into  the  reaction  mixture;  and  (c)  analysis  of CTL 
specificities  using  cloned  CTL  populations.  Our  results  thus  indicate  that  H-2 
restriction of tumor-specific CTL activity can be directed  at the target cell level by 
variations in the expression of H-2 antigens. 
Received  for publication 29June 1981 and in revised  form 31 August  1981. 
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